Table 2 Characteristics of patients taking standard (20 mg) or reduced (15 mg) dose rivaroxaban
|  | Reduced Dose (15 mg daily) | Standard Dose (20 mg daily) | P-value |
|---|---|---|---|
Total number of patients | 6467 | 13,245 | Â |
Age Category, years |  |  | < 0.001 |
 65–69 | 7.9% | 18.2% |  |
 70 to 74 | 14.8% | 29.0% |  |
 75 to 79 | 20.7% | 25.6% |  |
 80 to 84 | 25.4% | 17.0% |  |
 85 to 89 | 19.8% | 7.8% |  |
 90 or over | 11.4% | 2.4% |  |
Sex |  |  | < 0.001 |
 Female | 57.1% | 46.2% |  |
 Male | 42.9% | 53.8% |  |
Race Category |  |  | < 0.001 |
 White | 85.2% | 85.8% |  |
 Black | 9.0% | 8.0% |  |
 Hispanic | 2.2% | 1.6% |  |
 Asian | 0.8% | 0.8% |  |
 Other | 2.8% | 3.8% |  |
 Smoking | 20.2% | 22.8% | < 0.001 |
 Alcohol | 2.3% | 3.2% | < 0.001 |
Weight Category (based on ICD-9 and ICD-10 codes for BMI Category) |  |  | < 0.001 |
 Under-Weight | 2.3% | 1.3% |  |
 Healthy or Overweight | 19.1% | 14.3% |  |
 Obese or Severe Obese | 26.2% | 31.2% |  |
 Not available | 52.4% | 53.2% |  |
Comorbid Conditions | |||
 Prior Stroke | 28.2% | 22.4% | < 0.001 |
 Prior major bleeding from Diagnosis | 26.6% | 23.9% | < 0.001 |
 Gastrointestinal bleeding | 15.2% | 13.5% | 0.002 |
 Cerebral bleeding | 1.3% | 0.8% | < 0.001 |
 Diabetes | 51.0% | 47.7% | < 0.001 |
 Prior AMI | 9.0% | 5.7% | < 0.001 |
 Liver Disease | 2.9% | 3.1% | 0.35 |
 Heart Failure | 35.6% | 24.3% | < 0.001 |
 Hypertension | 94.6% | 92.1% | < 0.001 |
 Ischemic cardiomyopathy | 47.7% | 40.2% | < 0.001 |
 Pulmonary | 15.9% | 11.1% | < 0.001 |
 COPD | 36.3% | 31.4% | < 0.001 |
 Transfusion from Procedure | 5.0% | 2.3% | < 0.001 |
 Revascularization | 16.5% | 13.7% | < 0.001 |
 Implantable Devices | 16.7% | 12.5% | < 0.001 |
 Valve Disease | 40.6% | 36.4% | 0.002 |
Renal Disease (ICD-9 and ICD-10 codes) |  |  | < 0.001 |
 None or Mild (Stage I, II) | 54.8% | 83.9% |  |
 Moderate (Stage III) | 37.5% | 14.5% |  |
 Severe (Stage IV, V) | 7.7% | 1.5% |  |
Concurrent Drugs (+/− 90 days of initiating DOAC) | |||
 SSRI/SNRI | 33.7% | 29.1% | < 0.001 |
 Strong and moderate P-GP inhibitors | 18.3% | 18.5% | 0.63 |
 P-GP inducers | 18.5% | 16.5% | < 0.001 |
 Strong P-GP and CYP3A4 dual inhibitors | 22.7% | 20.8% | 0.002 |
 P-GP and CYP3A4 inducers | 18.5% | 16.5% | < 0.001 |
 ACE inhibitors | 67.4% | 64.3% | < 0.001 |
 Warfarin | 15.0% | 16.1% | 0.045 |
 Angiotensin receptor blockers | 40.0% | 36.7% | < 0.001 |
 Beta blockers | 88.1% | 86.5% | 0.015 |
 Calcium channel blockers | 64.5% | 59.4% | < 0.001 |
 Digoxin | 23.1% | 20.8% | < 0.001 |
 Proton pump inhibitors | 58.3% | 52.3% | < 0.001 |
 NSAIDs | 52.9% | 50.1% | < 0.001 |
 Antiplatelets | 30.2% | 24.3% | < 0.001 |
 Insulin | 14.3% | 10.8% | < 0.001 |
 Statins | 79.3% | 77.6% | 0.006 |
 Antiarrhythmics | 40.4% | 43.1% | < 0.001 |
Estimated Glomerular Filtration rate (ml/min/1.73 m2) |  |  | < 0.001 |
  < 30 | 7.5% | 1.3% |  |
 30–60 | 61.1% | 35.2% |  |
 60–90 | 28.8% | 56.7% |  |
  > =90 | 2.6% | 6.8% |  |
CCI(Charlson Comorbodity Index), mean (standard deviation) | 5.05(3.65) | 3.71(3.34) | < 0.001 |